Trial Profile
Study of impact of sequential ICI/TKI therapy on the risk of hepatotoxicity in patients with non-small-cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Sep 2018 New trial record
- 08 Sep 2018 Results published in the Journal of Thoracic Oncology